Thompson Davis & Co’s Accelerate Diagnostics AXDX Stock Holding History

Thompson Davis & Co’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-25	Closed	-$7K	–	1114
2016 Q3	$7K	Buy	25 +12	+92%	+$2.65K	0.01%	735
2016 Q2	$2K	Buy	+13	New	+$1.74K	﹤0.01%	937
2015 Q4	–	Sell	-25	Closed	-$4K	–	1127
2015 Q3	$4K	Hold	25	–	–	0.01%	871
2015 Q2	$6K	Buy	+25	New	+$5.97K	0.01%	842
2014 Q4	–	Sell	-50	Closed	-$11K	–	1177
2014 Q3	$11K	Buy	50 +25	+100%	+$4.86K	0.01%	660
2014 Q2	$7K	Sell	25 -13	-34%	-$2.84K	0.01%	540
2014 Q1	$8K	Buy	+38	New	+$5.63K	0.01%	533

Other funds holding AXDX

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Thompson Davis & Co's AXDX Position: Q4 2016 in Review

Thompson Davis & Co sold out of Accelerate Diagnostics (AXDX) in Q4 2016, closing a stake of 25 shares — an estimated $7K sold.

Thompson Davis & Co first reported a position in AXDX in Q1 2014 and held it in 7 quarters. The position peaked at $11K in Q3 2014. 109 funds tracked by Wall St. Rank hold AXDX as of Q4 2016.

Thompson Davis & Co reported no remaining Accelerate Diagnostics position as of Q4 2016 after selling out during the quarter.
Thompson Davis & Co sold 25 Accelerate Diagnostics shares in Q4 2016, an estimated $7K.
Thompson Davis & Co first reported a position in Accelerate Diagnostics in Q1 2014 and held it in 7 quarters.
Thompson Davis & Co's Accelerate Diagnostics position peaked at $11K in Q3 2014.
109 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2016.

Based on Thompson Davis & Co's 13F filing for Q4 2016, filed 7 Feb 2017.